Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
EL&P Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Celyad Sa ADR
(NQ:
CYAD
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 18, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Celyad Sa ADR
Publication of a transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
September 07, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
September 05, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
September 04, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
August 24, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology announces receipt of Nasdaq delisting notice
May 15, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
May 05, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology reports first quarter 2023 financial results and recent business highlights
May 05, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology announces receipt of Nasdaq initial notification on ADS bid price
April 24, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology announces receipt of Nasdaq notice
April 04, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology appoints Georges Rawadi as its new CEO
March 24, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology reports full year 2022 financial results and recent business highlights
March 23, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology to announce full year 2022 financial results and host conference call
March 17, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology announces non-cash impairment
March 15, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
REPEAT -- Celyad Oncology SA - Letter to Shareholders
March 01, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology SA - Letter to Shareholders
February 28, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology announces the publication of data from its Phase 1 THINK study of CYAD-01
February 09, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology provides fourth quarter 2022 business update and 2023 outlook
February 03, 2023
From
Celyad Oncology SA
Via
GlobeNewswire
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
January 19, 2023
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property
December 21, 2022
From
Celyad Oncology SA
Via
GlobeNewswire
Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
November 10, 2022
From
Celyad Oncology SA
Via
GlobeNewswire
Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations Transaction
September 20, 2022
From
Cellistic
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.